These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 18559355)

  • 1. Is special FDA regulation of nanomedicine needed? A conversation with Norris E. Alderson. Interview by Barbara J Culliton.
    Alderson NE
    Health Aff (Millwood); 2008; 27(4):w315-7. PubMed ID: 18559355
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Beyond biotechnology: FDA regulation of nanomedicine.
    Miller J
    Columbia Sci Technol Law Rev; 2003; 4():E5. PubMed ID: 15977335
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nanomedicine: An unresolved regulatory issue.
    Chan VS
    Regul Toxicol Pharmacol; 2006 Dec; 46(3):218-24. PubMed ID: 17081666
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nanomedicine--the power of proteins: a conversation with Lance Liotta and Emanual Petricoin. Interview by Barbara J Culliton.
    Liotta L; Petricoin E
    Health Aff (Millwood); 2008; 27(4):w310-4. PubMed ID: 18559354
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inorganic hollow nanoparticles and nanotubes in nanomedicine Part 1. Drug/gene delivery applications.
    Son SJ; Bai X; Lee SB
    Drug Discov Today; 2007 Aug; 12(15-16):650-6. PubMed ID: 17706547
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multifunctional nanoparticles--properties and prospects for their use in human medicine.
    Sanvicens N; Marco MP
    Trends Biotechnol; 2008 Aug; 26(8):425-33. PubMed ID: 18514941
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nanoparticle therapeutics: FDA approval, clinical trials, regulatory pathways, and case study.
    Eifler AC; Thaxton CS
    Methods Mol Biol; 2011; 726():325-38. PubMed ID: 21424459
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Emerging trends of nanomedicine--an overview.
    Sandhiya S; Dkhar SA; Surendiran A
    Fundam Clin Pharmacol; 2009 Jun; 23(3):263-9. PubMed ID: 19527298
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Exploring emerging nanobiotechnology drugs and medical devices.
    Paradise J; Diliberto GM; Tisdale AW; Kokkoli E
    Food Drug Law J; 2008; 63(2):407-20. PubMed ID: 18561467
    [No Abstract]   [Full Text] [Related]  

  • 10. The need for rules and regulations.
    Helmus MN
    Nat Nanotechnol; 2007 Jun; 2(6):333-4. PubMed ID: 18654297
    [No Abstract]   [Full Text] [Related]  

  • 11. Insurers and 'targeted biologics' for cancer: a conversation with Lee N. Newcomer. Interview by Barbara J. Culliton.
    Newcomer LN
    Health Aff (Millwood); 2008; 27(1):w41-51. PubMed ID: 18042562
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nanoparticle formulations in pulmonary drug delivery.
    Bailey MM; Berkland CJ
    Med Res Rev; 2009 Jan; 29(1):196-212. PubMed ID: 18958847
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Promoting medical innovation while developing sound social and business policy: a conversation with Thomas G. Roberts. Interview by Barbara J. Culliton.
    Roberts TG
    Health Aff (Millwood); 2008; 27(1):w34-40. PubMed ID: 18042561
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Regulating nanomedicine.
    Nat Mater; 2007 Apr; 6(4):249. PubMed ID: 17401411
    [No Abstract]   [Full Text] [Related]  

  • 15. Applications for site-directed molecular imaging agents coupled with drug delivery potential.
    Wang H; Chen X
    Expert Opin Drug Deliv; 2009 Jul; 6(7):745-68. PubMed ID: 19552614
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nanosilver: a test for nanotech regulation.
    Wilhelmi B
    Food Drug Law J; 2008; 63(1):89-112. PubMed ID: 18561456
    [No Abstract]   [Full Text] [Related]  

  • 17. Regulatory perspective on the importance of ADME assessment of nanoscale material containing drugs.
    Zolnik BS; Sadrieh N
    Adv Drug Deliv Rev; 2009 Jun; 61(6):422-7. PubMed ID: 19389437
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bringing nanomedicines to market: regulatory challenges, opportunities, and uncertainties.
    Nijhara R; Balakrishnan K
    Nanomedicine; 2006 Jun; 2(2):127-36. PubMed ID: 17292125
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Regulatory agency consideration of pharmacogenomics.
    Pendergast MK
    Exp Biol Med (Maywood); 2008 Dec; 233(12):1498-503. PubMed ID: 18849547
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Medical devices: the obvious, the readily-accepted, and the surprising.
    Tolomeo DE; Clarke LA
    J Health Life Sci Law; 2008 Jul; 1(4):117, 119-44. PubMed ID: 18717154
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.